Replimune Group (REPL)
(Delayed Data from NSDQ)
$8.82 USD
+0.06 (0.68%)
Updated Jun 25, 2024 04:00 PM ET
After-Market: $8.81 -0.01 (-0.11%) 5:46 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
Replimune Group, Inc. [REPL]
Reports for Purchase
Showing records 101 - 120 ( 194 total )
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Program Updates. Several Trial Read-Outs in 2021.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
SITC Posters Impress; FY2Q21 Financials Reported; Raising PT to $58
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
SITC 2020 Abstract Preview for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
"Consider Reading" Vol. 18: Overcoming Resistance to Anti-PD-1 Therapy with Oncolytic Viruses
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T